VIDEO: SGLT2 inhibition helpful for managing residual cardiometabolic risk
Click Here to Manage Email Alerts
Key takeaways:
- In a patient with CAD and type 2 diabetes, switching to an SGLT2 inhibitor resulted in several health improvements.
- SGLT2 inhibitors should be considered in patients at high CV risk.
In this Healio | Cardiology Today video exclusive, Chad Morreale, DO, discusses his presentation at the National Lipid Association Scientific Sessions: “Cardiometabolic Disease Patient – How Do I Approach Residual Risk?”
Morreale, who is an NLA lipid scholar and a cardiovascular disease fellow, PGY-5, at Advocate Lutheran General Hospital, provided a case example and discussed the significance of SGLT2 inhibition for the treatment of residual cardiometabolic risk in patients with established CAD and type 2 diabetes.
“The big take-home points were anyone with cardiovascular disease, renal disease, history of heart failure, all should be on SGLT2 inhibitors as a first-line agent to reduce all-cause mortality, cardiovascular mortality, renal mortality and heart failure hospitalization,” Morreale said.
Watch the video for more.
Reference:
- Morreale C. Cardiometabolic Disease Patient – How Do I Approach Residual Risk? Presented at: National Lipid Association Scientific Sessions; June 1-4, 2023; Atlanta, Georgia (hybrid meeting).
Collapse
Healio Interviews
Click Here to Manage Email Alerts